Athira Pharma Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
LONA$4.02-10.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(81,937) | $(90,387) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 8,820 | 8,395 |
| Depreciation expense | 727 | 724 |
| Non-cash lease expense | 178 | 158 |
| Amortization of premiums and accretion of discounts on available-for-sale securities, net | (488) | (1,131) |
| Loss on disposal of equipment | 7 | — |
| Changes in operating assets and liabilities: | ||
| Unbilled grant receivable | — | 1,227 |
| Prepaid expenses and other current and long-term assets, net | 2,930 | (366) |
| Accounts payable and accrued liabilities | (1,123) | 7,159 |
| Operating lease liability | (271) | (239) |
| Net cash used in operating activities | (71,157) | (74,460) |
| Investing activities | ||
| Purchases of available-for-sale securities | (11,322) | (27,671) |
| Maturities of available-for-sale securities | 68,997 | 116,673 |
| Purchases of property and equipment | (33) | (304) |
| Net cash provided by investing activities | 57,642 | 88,698 |
| Financing activities | ||
| Proceeds from exercise of common stock options and issuance of common stock under employee stock purchase plan | 160 | 341 |
| Net cash provided by financing activities | 160 | 341 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (13,355) | 14,579 |
| Cash, cash equivalents and restricted cash, beginning of period | 91,215 | 96,386 |
| Cash, cash equivalents and restricted cash, end of period | $77,860 | $110,965 |
ATHIRA PHARMA, INC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.